AKBA Q3'26 Earnings: EPS estimate is (0.04) USD

What happened

Akebia Therapeutics is set to report its Q3'26 results on November 5 before the market opens, with the announcement expected at 9:30 a.m. ET. The supplied estimate is revenue of $46.94 million and earnings per share, or profit or loss per share, of $(0.04).

Confirmed

Global impact / market context

The estimates provide a benchmark for judging the quarter: revenue below the forecast could indicate weaker sales, while a larger per-share loss could suggest higher costs or less income. Reported results may shape views of Akebia’s ability to generate revenue and control spending.

Analyst inference

The article lists revenue estimates alongside reported results from earlier quarters, and reports negative earnings per share in the last three quarters shown. Comparing the upcoming figures with that history can help investors assess whether sales and the loss per share are improving or weakening.

Confirmed

What to watch

1. Check the reported Q3'26 revenue against the $46.94 million estimate; the difference would show whether sales were higher or lower than the supplied benchmark. Analyst inference
2. Compare reported earnings per share with the $(0.04) estimate to see whether Akebia’s loss per share was smaller or larger than expected. Analyst inference
3. Watch the company’s announcement for explanations of sales and costs, since those details could clarify what drove any difference from the estimates. Analyst inference

Evidence

• Original source link unavailable